Waldenström macroglobulinemia: from biology to treatment

References

• Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al. Waldenstrom's macroglobulinemia: clinical features, complications and management. J Clin Oncol 2000;18(1):214-26
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol 2003;4(11):679-85
   PubMed Web of Science ®Google Scholar
• Kyle RA, Anderson KC. A tribute to Jan Gosta Waldenstrom. Blood 1997;89(12):4245-7
   PubMed Web of Science ®Google Scholar
• Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30(2):110-15
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 2005;23:1564-77
   PubMed Web of Science ®Google Scholar
• Herrinton LJ, Weiss NS. Incidence of Waldenstrom's macroglobulinemia. Blood 1993;82(10):3148-50
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J Clin 2005;55(1):10-30
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer Facts & Figures 2012. American Cancer Society; Atlanta, GA, USA: 2012
   Google Scholar
• Sahota SS, Forconi F, Ottensmeier CH, et al. Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood 2002;100(4):1505-7
   PubMed Web of Science ®Google Scholar
• Schop RF, Kuehl WM, Van Wier SA, et al. Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 2002;100(8):2996-3001
   PubMed Web of Science ®Google Scholar
• Braggio E, Keats JJ, Leleu X, et al. High-resolution genomic analysis in Waldenstrom's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas. Clin Lymphoma Myeloma 2009;9(1):39-42
   PubMedGoogle Scholar
• Chang H, Qi X, Xu W, et al. Analysis of 6q deletion in Waldenstrom macroglobulinemia. Eur J Haematol 2007;79(3):244-7
   PubMed Web of Science ®Google Scholar
• Braggio E, Keats JJ, Leleu X, et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res 2009;69(8):3579-88
   PubMed Web of Science ®Google Scholar
• Gutierrez NC, Ocio EM, De Las Rivas J, et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 2007;21(3):541-9
   PubMed Web of Science ®Google Scholar
• Poulain S, Braggio E, Roumier C, et al. High-throughput genomic analysis in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11(1):106-8
   PubMed Web of Science ®Google Scholar
• Turner CA Jr, Mack DH, Davis MM. BLIMP-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell 1994;77(2):297-306
   PubMed Web of Science ®Google Scholar
• Nguyen-Khac F, Lambert J, Chapiro E, et al. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom's macroglobulinemia. Haematologica 2013;98(4):649-54
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med 2012;367(9):826-33
   PubMed Web of Science ®Google Scholar
• Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 2013;121(11):2051-8
   PubMed Web of Science ®Google Scholar
• Varettoni M, Arcaini L, Zibellini S, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood 2013;121(13):2522-8
   PubMed Web of Science ®Google Scholar
• Gachard N, Parrens M, Soubeyran I, et al. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia 2013;27(1):183-9
   PubMed Web of Science ®Google Scholar
• Jimenez C, Sebastian E, Chillon MC, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom's macroglobulinemia. Leukemia 2013;27(8):1722-8
   PubMed Web of Science ®Google Scholar
• Poulain S, Roumier C, Decambron A, et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood 2013;121(22):4504-11
   PubMed Web of Science ®Google Scholar
• Mori N, Ohwashi M, Yoshinaga K, et al. L265P Mutation of the MYD88 Gene Is Frequent in Waldenstrom's Macroglobulinemia and Its Absence in Myeloma. PLoS ONE 2013;8(11):e80088
   PubMed Web of Science ®Google Scholar
• Ondrejka SL, Lin JJ, Warden DW, et al. MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders. Am J Clin Pathol 2013;140(3):387-94
   PubMed Web of Science ®Google Scholar
• Landgren O, Staudt L. MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med 2012;367(23):2255-6
   PubMed Web of Science ®Google Scholar
• Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997;278(5343):1612-15
   PubMed Web of Science ®Google Scholar
• Wesche H, Henzel WJ, Shillinglaw W, et al. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 1997;7(6):837–47
   PubMed Web of Science ®Google Scholar
• Bianchi G, Sacco A, Kumar S, et al. Candidate genes of Waldenstrom's macroglobulinemia: current evidence and research. Appl Clin Genet 2013;6:33-42
   PubMedGoogle Scholar
• Hunter Z, Xu L, Yang G, et al. The genomic landscape of Waldenstom's Macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 2013
   Web of Science ®Google Scholar
• Roccaro AM, Sacco A, Jimenez C, et al. A novel activating mutation of CXCR4 plays a crucial role in waldenstrom macroglobulinemia biology. Blood (ASH annual meeting abstracts) 2013;122(21):272
   Web of Science ®Google Scholar
• Cao Y, Xu L, Liu X, et al. Whole genome sequencing identifies recurring somatic mutations in the C-Terminal domain of CXCR4, including a gain of function mutation in waldenstrom's macroglobinemia. Blood (ASH annual meeting abstracts) 2013;120(21):2715
   Web of Science ®Google Scholar
• Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 2006;94(2):179-183
   Web of Science ®Google Scholar
• Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 2007;96(Suppl):R26-30
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetics in cancer. N Engl J Med 2008;358(11):1148-59
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Sacco A, Chen C, et al. MicroRNA expression in the biology, prognosis and therapy of Waldenstrom macroglobulinemia. Blood 2009;113(18):4391-402
   PubMed Web of Science ®Google Scholar
• Sacco A, Ghobrial IM, Roccaro AM. Epigenetics in Waldenstrom's macroglobulinemia. Epigenomics 2010;2(5):691-6
   PubMed Web of Science ®Google Scholar
• Calin GA, Cimmino A, Fabbri M, et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A 2008;105(13):5166-71
   PubMed Web of Science ®Google Scholar
• Chng WJ, Schop RF, Price-Troska T, et al. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood 2006;108(8):2755-63
   PubMed Web of Science ®Google Scholar
• Trojani A, Greco A, Tedeschi A, et al. Microarray demonstrates different gene expression profiling signatures between Waldenstrom macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Clin Lymphoma Myeloma Leuk 2013;13(2):208-10
   PubMed Web of Science ®Google Scholar
• Hatjiharissi E, Ngo H, Leontovich AA, et al. Proteomic analysis of waldenstrom macroglobulinemia. Cancer Res 2007;67(8):3777-84
   PubMed Web of Science ®Google Scholar
• Gottipati S, Rao NL, Fung-Leung WP. IRAK1: a critical signaling mediator of innate immunity. Cell Signal 2008;20(2):269-76
   PubMed Web of Science ®Google Scholar
• Yang G, Zhou Y, Liu X, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood 2013;122(7):1222-32
   PubMed Web of Science ®Google Scholar
• Treon SP, Hunter ZR. A new era for Waldenstrom macroglobulinemia: MYD88 L265P. Blood 2013;121(22):4434-6
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2(7):489-501
   PubMed Web of Science ®Google Scholar
• Leleu X, Jia X, Runnels J, et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2007;110(13):4417-26
   PubMed Web of Science ®Google Scholar
• Sacco A, Roccaro A, Ghobrial IM. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. Oncotarget 2010;1(7):578-82
   PubMedGoogle Scholar
• Yang G, Liu X, Zhou Y, et al. PI3K/AKT Pathway Is Activated By MYD88 L265P and Use Of PI3K-Delta Inhibitors Induces Robust Tumor Cell Killing In Waldenstrom's Macroglobulinemia. Blood (ASH annual meeting abstracts) 2013;122(21):4255
   Google Scholar
• Roccaro AM, Sacco A, Husu EN, et al. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 2010;115(3):559-69
   PubMed Web of Science ®Google Scholar
• Hodge LS, Ansell SM. Jak/Stat pathway in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11(1):112-14
   PubMed Web of Science ®Google Scholar
• Elsawa SF, Novak AJ, Ziesmer SC, et al. Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. Blood 2011;118(20):5540-9
   PubMed Web of Science ®Google Scholar
• Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004;18(18):2195-224
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Leleu X, Sacco A, et al. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2008;111(9):4752-63
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Sacco A, Aujay M, et al. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood 2010;115(20):4051-60
   PubMed Web of Science ®Google Scholar
• Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone and rituximab: WMCTG clinical trial 05–180. J Clin Oncol 2009;27(23):3830-5
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia. Am J Hematol 2010;85(9):670-4
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28(8):1422-8
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003;102(10):3759-64
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106(3):812-17
   PubMed Web of Science ®Google Scholar
• Varettoni M, Zibellini S, Arcaini L, et al. MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. Blood 2013;122(13):2284-5
   PubMed Web of Science ®Google Scholar
• Kyle RA, Garton JP. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc 1987;62(8):719-31
   PubMed Web of Science ®Google Scholar
• Leleu X, Moreau AS, Weller E, et al. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma 2008;49(6):1104-7
   PubMed Web of Science ®Google Scholar
• Schop RF, Van Wier SA, Xu R, et al. 6q deletion discriminates Waldenstrom macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet 2006;169(2):150-3
   PubMedGoogle Scholar
• Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol 2006;17(3):488-94
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Bjorkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. Blood 2008;112(8):3052-6
   PubMed Web of Science ®Google Scholar
• Vos JM, Minnema MC, Wijermans PW, et al. Guideline for diagnosis and treatment of Waldenstrom's macroglobulinaemia. Neth J Med 2013;71(2):54-62
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Witzig TE. Waldenstrom macroglobulinemia. Curr Treat Options Oncol 2004;5(3):239-47
   PubMedGoogle Scholar
• Hunter ZR, Branagan AR, Manning R, et al. CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia. Clin Lymphoma 2005;5(4):246-249
   PubMedGoogle Scholar
• Ghobrial IM. Are you sure this is Waldenstrom macroglobulinemia? Hematology Am Soc Hematol Educ Program 2012;586-94
   PubMed Web of Science ®Google Scholar
• Gertz MA. Waldenstrom macroglobulinemia: 2012 update on diagnosis, risk stratification and management. Am J Hematol 2012;87(5):503-10
   PubMed Web of Science ®Google Scholar
• Kyle RA, Benson JT, Larson DR, et al. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood 2012;119(19):4462-6
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Fonseca R, Gertz MA, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006;133(2):158-64
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 2001;98(1):41-8
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Hamilos G, Zervas K, et al. Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia. Ann Oncol 2003;14(8):1299-305
   PubMed Web of Science ®Google Scholar
• Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30(2):116-20
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Gika D, Zervas K, et al. The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemia. Leuk Lymphoma 2004;45(9):1809-13
   PubMed Web of Science ®Google Scholar
• Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009;113(18):4163-70
   PubMed Web of Science ®Google Scholar
• Van Den Brand M, Van Krieken JH. Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review. Haematologica 2013;98(7):1003-13
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Garand R, Lode L, et al. 14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia. Semin Oncol 2003;30(2):153-155
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2009;27(1):120-6
   PubMed Web of Science ®Google Scholar
• Gertz MA. Waldenstrom macroglobulinemia: is newer really better? Leuk Lymphoma 2010;51(12):2152-3
   PubMed Web of Science ®Google Scholar
• Treon SP, Patterson CJ, Kimby E, et al. Advances in the biology and treatment of Waldenstrom's macroglobulinemia: a report from the 5th International Workshop on Waldenstrom's Macroglobulinemia, Stockholm, Sweden. Clin Lymphoma Myeloma 2009;9(1):10-15
   PubMedGoogle Scholar
• Anderson KC, Alsina M, Bensinger W, et al. Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma, version 2. 2013. J Natl Compr Canc Netw 2012;10(10):1211-19
   PubMed Web of Science ®Google Scholar
• Owen RG, Kyle RA, Stone MJ, et al. Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop. Br J Haematol 2013;160(2):171-6
   PubMed Web of Science ®Google Scholar
• Blum W, Porcu P. Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome. Semin Thromb Hemost 2007;33(4):350-4
   PubMed Web of Science ®Google Scholar
• Stone MJ, Bogen SA. Role of plasmapheresis in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013;13(2):238-40
   PubMed Web of Science ®Google Scholar
• Rourke M, Anderson KC, Ghobrial IM. Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leuk Lymphoma 2010;51(10):1779-92
   PubMed Web of Science ®Google Scholar
• Treon SP. How I treat Waldenstrom macroglobulinemia. Blood 2009;114(12):2375-85
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Zervas C, Zomas A, et al. Extended rituximab therapy for previously untreated patients with Waldenstrom's macroglobulinemia. Clin Lymphoma 2002;3(3):163-6
   PubMedGoogle Scholar
• Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 2002;20(9):2327-33
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab and cyclophosphamide. J Clin Oncol 2007;25(22):3344-9
   PubMed Web of Science ®Google Scholar
• Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11(1):133-5
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Roussou M, Kastritis E, et al. Primary treatment of Waldenstrom's macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): final analysis of a phase II study. Blood (ASH Annual meeting abstracts) 2012;120(21): 438
   Web of Science ®Google Scholar
• Rummel MJ, Lerchenmüller C, Greil R, et al. Bendamustine-Rituximab Induction Followed by Observation or Rituximab Maintenance for Newly Diagnosed Patients with Waldenström's Macroglobulinemia: Results From a Prospective, Randomized, Multicenter Study (StiL NHL 7–2008–MAINTAIN; ClinicalTrials.gov Identifier: NCT00877214). Blood (ASH Annual meeting abstracts) 2012;(21):2739
   Google Scholar
• Treon SP, Hanzis C, Manning RJ, et al. Maintenance Rituximab is associated with improved clinical outcome in rituximab naive patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol 2011;154(3):357-62
   PubMed Web of Science ®Google Scholar
• Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol 2013;31(3):301-7
   PubMed Web of Science ®Google Scholar
• Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009;27(2):250-5
   PubMed Web of Science ®Google Scholar
• Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 2009;113(16):3673-8
   PubMed Web of Science ®Google Scholar
• Tam CS, Wolf M, Prince HM, et al. Fludarabine, cyclophosphamide and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 2006;106(11):2412-20
   PubMed Web of Science ®Google Scholar
• Tedeschi A, Benevolo G, Varettoni M, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer 2012;118(2):434-43
   PubMed Web of Science ®Google Scholar
• Issa GC, Leblebjian H, Roccaro AM, Ghobrial IM. New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia. Curr Opin Hematol 2011;18(4):260-5
   PubMed Web of Science ®Google Scholar
• Treon SP, Patterson CJ, Munshi NC, Anderson KC. Proceedings of the Seventh International Workshop on Waldenstrom Macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013;13(2):181-3
   PubMed Web of Science ®Google Scholar
• Sacco A, Aujay M, Morgan B, et al. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. Clin Cancer Res 2011;17(7):1753-64
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Sheehy P, et al. Prospective Phase II Clinical Trial of Carfilzomib, rituximab and Dexamethasone (CARD) in Patients with Symptomatic Waldenstrom's Macroglobulinemia (WM) [Abstract]. IWWM-7; 2012
   Google Scholar
• Ghobrial IM, Gertz M, Laplant B, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28(8):1408-14
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Boswell E, Banwait R, et al. Phase I trial of everolimus and rituximab or everolimus, bortezomib and rituximab in relapsed or relapsed/refractory waldenstrom's macroglobulinemia. Blood (ASH Annual meeting abstracts) 2011;118(21):2705
   Web of Science ®Google Scholar
• Ghobrial IM, Moreau P, Harris B, et al. A multicenter Phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia. Clin Cancer Res 2012;18(18):5043-50
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Roccaro A, Hong F, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res 2010;16(3):1033-41
   PubMed Web of Science ®Google Scholar
• Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008;112(12):4452-7
   PubMed Web of Science ®Google Scholar
• Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res 2009;15(1):355-60
   PubMed Web of Science ®Google Scholar
• Sheeba KT, Donna MW, Michael W, et al. A Phase I Trial of Pomalidomide in Patients with Relapsed and/or Refractory Waldenström's Macroglobulinemia (WM). IWWM–7 Session-9; 2012
   Google Scholar
• Treon SP, Tripsas C, Warren D, et al. Phase I Study of Pomalidomide, Dexamethasone and Rituximab (PDR) in Patients with Relapsed or Refractory Waldenstrom's Macroglobulenima. Hematol Oncol (Abstract) 2013;31(S1):536
   Google Scholar
• Grant S. Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors. Leuk Lymphoma 2011;52(9):1623-5
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Campigotto F, Murphy TJ, et al. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia. Blood 2013;121(8):1296-303
   PubMed Web of Science ®Google Scholar
• Yang G, Xu L, Zhou Y, et al. Participation of BTK in MYD88 signaling in malignant cells expressing the L265P mutation in Waldenstrom's macroglobulinemia and effect on tumor cell with BTK-inhibitor PCI-32765 in combination with MYD88 pathway inhibitors [abstract]. J Clin Oncol 2012;30(Suppl):Abstract 8106
   Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31(1):88-94
   PubMed Web of Science ®Google Scholar